By: IPP Bureau
Last updated : March 09, 2022 10:47 am
Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
AIkido Pharma has entered into a Master Collaboration Agreement (MCA) with Cedars-Sinai Medical Center. The purpose of the MCA is to collaborate in the funding and commercialization of discoveries and technologies developed at Cedars-Sinai.
Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. Cedars-Sinai is known for its exceptional patient care, leading-edge medical research, comprehensive healthcare education, and wide-ranging community benefit activities.
Under the MCA, AIkido will be working with Cedars-Sinai's Technology Ventures team, whose mission is to identify, protect and support the commercialization of discoveries and technologies developed at Cedars-Sinai or its partner institutions. Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021.
Anthony Hayes, CEO of AIkido Pharma stated, "Cedars-Sinai is a world-class institution, and we are honoured to be working with them. The team at Technology Ventures consists of experts in intellectual property portfolio management and licensing, legal affairs and finance who have a proven track record of monetizing exceptional technology. It's a privilege to be involved and to be working together to advance innovative patient care and research."